pharmaphorum

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
findnerd.com

jQuery .prop() vs .attr()

Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...
Medscape

NICE Endorses Vutrisiran for ATTR-CM Treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
Everyday Health

What You Need to Know About ATTR-CM When You’re an Older Adult

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...
BioSpace

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
Seeking Alpha

Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade)

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...
FiercePharma

Alnylam's Amvuttra blows past estimates again as ATTR-CM launch gains traction

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...
FierceBiotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized

Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 44% to $14.34 in early trading Monday. The ...
pharmaphorum

CRISPR biotech Intellia plummets as trial paused for safety

Gene-editing specialist Intellia Therapeutics lost more than 45% of its value in pre-market trading today as it revealed phase 3 trials of one of its two priority programmes had been suspended due to ...
Healthline

What to Know About Transthyretin Amyloidosis (ATTR) Genetic Testing

Genetic testing for ATTR can detect transthyretin mutations and offer crucial information about risk, monitoring, and treatment, if needed. Transthyretin amyloidosis (ATTR) is a genetic condition that ...
Business Wire

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – − Additional Analyses ...